ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,704.00
-0.60%
S&P ASX All Technology
3,069.60
-0.30%
Brent Oil
86.665
0.16%
US Dollar vs AUD
1.50634
0.23%
Bitcoin
63,117.53
0.43%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Lixte Biotechnology Holdings Inc (LIXTW)

  7. Lixte Biotechnology Holdings Inc (LIXTW) News

LIXTW

Lixte Biotechnology (LIXTW)

Lixte Biotechnology Holdings Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:LIXTW
DateTimeSourceHeadlineSymbolCompany
15/06/202404:47Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LIXTWLixte Biotechnology Holdings Inc
15/06/202401:00GlobeNewswire Inc.LIXTE Biotechnology Holdings announces collaboration on a New Colon Cancer Clinical TrialNASDAQ:LIXTWLixte Biotechnology Holdings Inc
14/06/202423:30GlobeNewswire Inc.LIXTE Biotechnology Holdings to Collaborate with Roche and Netherlands Cancer Institute in New Colon Cancer Clinical TrialNASDAQ:LIXTWLixte Biotechnology Holdings Inc
14/06/202422:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LIXTWLixte Biotechnology Holdings Inc
06/06/202422:30GlobeNewswire Inc.Scientific Journal Reports Findings that Show LIXTE’s Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune SystemNASDAQ:LIXTWLixte Biotechnology Holdings Inc
06/06/202405:55Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LIXTWLixte Biotechnology Holdings Inc
03/06/202422:30GlobeNewswire Inc.LIXTE Biotechnology Holdings Names Distinguished Oncologist Jan Schellens as Chief Medical OfficerNASDAQ:LIXTWLixte Biotechnology Holdings Inc
30/05/202407:29Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LIXTWLixte Biotechnology Holdings Inc
21/05/202407:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LIXTWLixte Biotechnology Holdings Inc
10/05/202402:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LIXTWLixte Biotechnology Holdings Inc
09/05/202422:30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LIXTWLixte Biotechnology Holdings Inc
08/05/202423:25GlobeNewswire Inc.LIXTE Biotechnology Co-Sponsoring International Scientific Conference on “Therapeutic Over-Activation in Cancer”NASDAQ:LIXTWLixte Biotechnology Holdings Inc
25/04/202405:25AllPennyStocks.comMixed Shelf Filing Gives Micro Cap Delayed BoostNASDAQ:LIXTWLixte Biotechnology Holdings Inc
28/03/202406:35AllPennyStocks.comBiotech Steals The Show Following Pre-Clinical Data AnnouncementNASDAQ:LIXTWLixte Biotechnology Holdings Inc
27/03/202423:30GlobeNewswire Inc.NEW SCIENTIFIC PUBLICATION SHOWS LB-100, LIXTE’S LEAD CLINICAL COMPOUND, CAN FORCE CANCER CELLS TO GIVE UP THEIR CANCER-CAUSING PROPERTIESNASDAQ:LIXTWLixte Biotechnology Holdings Inc
21/03/202423:30GlobeNewswire Inc.LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer TreatmentsNASDAQ:LIXTWLixte Biotechnology Holdings Inc
28/02/202400:30GlobeNewswire Inc.Professor René Bernards to Present New Pre-Clinical Data on LIXTE’s LB-100 at Joint Conference of European and American Associations for Cancer ResearchNASDAQ:LIXTWLixte Biotechnology Holdings Inc
27/02/202400:30GlobeNewswire Inc.LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCINASDAQ:LIXTWLixte Biotechnology Holdings Inc
30/01/202400:30GlobeNewswire Inc.First Patient Dosed with LIXTE’s LB-100 and GSK’s Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma TrialNASDAQ:LIXTWLixte Biotechnology Holdings Inc
14/11/202300:30GlobeNewswire Inc.LIXTE Biotechnology Provides Update on Clinical Progress and Expanding CollaborationsNASDAQ:LIXTWLixte Biotechnology Holdings Inc
16/10/202323:30GlobeNewswire Inc.LIXTE, Netherlands Cancer Institute, and Oncode Institute to Expand CollaborationNASDAQ:LIXTWLixte Biotechnology Holdings Inc
09/10/202323:30GlobeNewswire Inc.LIXTE Biotechnology Holdings Announces the Passing of its Founder, John S. KovachNASDAQ:LIXTWLixte Biotechnology Holdings Inc
26/09/202322:30GlobeNewswire Inc.LIXTE Appoints Bas van der Baan as President and Chief Executive OfficerNASDAQ:LIXTWLixte Biotechnology Holdings Inc
20/09/202322:30GlobeNewswire Inc.LIXTE Biotechnology Announces a Supported Collaborative Trial to Study LIXTE’s First-in-Class PP2A Inhibitor, LB-100, Plus GSK’s Immunotherapy, Dostarlimab, in Clear-Cell Ovarian CancerNASDAQ:LIXTWLixte Biotechnology Holdings Inc
21/07/202306:05GlobeNewswire Inc.LIXTE Biotechnology Announces Closing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq RulesNASDAQ:LIXTWLixte Biotechnology Holdings Inc
18/07/202322:00GlobeNewswire Inc.LIXTE Biotechnology Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq RulesNASDAQ:LIXTWLixte Biotechnology Holdings Inc
17/07/202322:30GlobeNewswire Inc.Preclinical Results of LIXTE Biotechnology’s Collaboration with Netherlands Cancer Institute Reveal Novel Mechanism by which LIXTE’s Lead Clinical Compound LB-100 Enhances Effectiveness of Immunotherapy and ChemotherapyNASDAQ:LIXTWLixte Biotechnology Holdings Inc
02/12/202004:30GlobeNewswire Inc.Lixte Biotechnology Holdings, Inc. Announces Closing of Public Offering and Uplisting to NasdaqNASDAQ:LIXTWLixte Biotechnology Holdings Inc
01/12/202007:52Business WireWestPark Capital Announces Closing of $5,700,000 Follow-On Offering & NASDAQ Up-listing of Lixte Biotechnology Holdings, Inc....NASDAQ:LIXTWLixte Biotechnology Holdings Inc
 Showing the most relevant articles for your search:NASDAQ:LIXTW

Your Recent History

ASX
WBC
Westpac Banking
ASX
ANZ
Australia And New Zealan...
FTSE
UKX
FTSE 100
FX
AUDUSD
AUD vs US Dollar
ASX
XTO
S&P ASX 100
NASDAQ
NVDA
NVIDIA
ASX
QBE
QBE Insurance
SPI
SP500
S&P 500
FX
AUDCAD
AUD vs CAD
ASX
CBA
Commonwealth Bank Of Aus...
ASX
WDC
Westfield
ASX
BHP
BHP
NYSE
KO
Coca Cola
FX
AUDJPY
AUD vs Yen
ASX
MQG
Macquarie
ASX
CSL
CSL
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved